Compare Charles River Laboratories Intl. Inc (CRL) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs US Bancorp — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while US Bancorp trades at $62.88 (market cap $96.80B). The key difference: US Bancorp is far larger — about 8.7× Charles River Laboratories Intl. Inc's market cap, and US Bancorp pays a 3.35% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | USB | |
|---|---|---|
Market Cap | $11.14B | $96.80B |
Sector | Health | Financials |
52-Week High | $233.60 | $62.89 |
52-Week Low | $145.57 | $43.94 |
Enterprise Value | $14.00B | — |
Dividend Yield | — | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
U.S. Bancorp (USB) trades at $62.34, near the lower end of analyst targets, with a modest daily decline. The stock shows bullish technical signals from moving averages and has consistently beaten earnings estimates in recent quarters. Revenue and net income have grown steadily, with 2025 net income reaching $7.57 billion. Recent news highlights new small business payment tools and positive earnings expectations for Q2 2026.
The outlook is supported by strong profitability and a favorable analyst consensus, but risks include elevated debt levels and interest rate sensitivity. The stock offers value with a P/E of 13.07 and a dividend, though net cash flow remains negative. Upside to the $67 consensus target depends on continued earnings execution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
